CYTOMX THERAPEUTICS, INC. (NASDAQ:CTMX) Files An 8-K Submission of Matters to a Vote of Security Holders

ME Staff 8-k
-
0
CYTOMX THERAPEUTICS, INC. (NASDAQ:CTMX) Files An 8-K Submission of Matters to a Vote of Security Holders

CYTOMX THERAPEUTICS, INC. (NASDAQ:CTMX) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07

CytomX Therapeutics, Inc. (the “Company”) held its 2019 Annual Meeting of Stockholders (the “Annual Meeting”) on June 19, 2019. On the April 22, 2019 record date, there were 45,311,464 shares of the Company’s common stock outstanding with each such share being entitled to one vote per share.

At the Annual Meeting, 38,541,136 shares of the Company’s common stock were voted in person or by proxy for the four proposals set forth below, each of which is described in the Company’s Definitive Proxy Statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 26, 2019.

Proposal 1. The Company’s stockholders elected the Class I director nominees below to the Company’s Board of Directors to hold office until the 2022 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or the earlier of their death, resignation or removal.

  101,024   875,938   1,446,514   6,981,005


About CYTOMX THERAPEUTICS, INC. (NASDAQ:CTMX)

CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company. The Company is engaged in the development of a class of antibody therapeutics based on its Probody technology platform. It uses its platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against a range of targets. A Probody therapeutic consists of three components produced as a single protein by standard antibody production methodology: an active anti-cancer antibody, a mask for the antibody and a protease-cleavable linker. Its Probody product candidate, CX-072, is directed against programmed death-ligand 1 (PD-L1). CX-072 is based on a monoclonal antibody targeting PD-L1. Its product candidate, CX-2009, is directed against the target CD-166. It is developing a programmed cell death protein 1 (PD-1) Probody therapeutic as an additional approach to block the PD-L1/PD-1 pathway. It is also conducting Integrin alpha-3 PDC program.